Margarita Pizarro1, Nancy Solís1, Pablo Quintero1, Francisco Barrera1, Daniel Cabrera1,2, Pamela Rojas-de Santiago1, Juan P Arab1, Oslando Padilla3, Juan C Roa4, Han Moshage5, Alexander Wree6, Eugenia Inzaugarat6, Ariel E Feldstein6, Carlos E Fardella7, Rene Baudrand7, Arnoldo Riquelme1, Marco Arrese1. 1. Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Departamento de Ciencias Químico-Biológicas, Universidad Bernardo O Higgins, Santiago, Chile. 3. Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. Departamento de Patología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 5. Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Department of Pediatrics, University of California, San Diego, CA, USA. 7. Departamento de Endocrinología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
BACKGROUND: Therapeutic options to treat Non-alcoholic steatohepatitis (NASH) are limited. Mineralocorticoid receptor (MR) activation could play a role in hepatic fibrogenesis and its modulation could be beneficial for NASH. AIM: To investigate whether eplerenone, a specific MR antagonist, ameliorates liver damage in experimental NASH. METHODS: C57bl6 mice were fed a choline-deficient and amino acid-defined (CDAA) diet for 22 weeks with or without eplerenone supplementation. Serum levels of aminotransferases and aldosterone were measured and hepatic steatosis, inflammation and fibrosis scored histologically. Hepatic triglyceride content (HTC) and hepatic mRNA levels of pro-inflammatory pro-fibrotic, oxidative stress-associated genes and of MR were also assessed. RESULTS: CDAA diet effectively induced fibrotic NASH, and increased the hepatic expression of pro-inflammatory, pro-fibrotic and oxidative stress-associated genes. Hepatic MR mRNA levels significantly correlated with the expression of pro-inflammatory and pro-fibrotic genes and were significantly increased in hepatic stellate cells obtained from CDAA-fed animals. Eplerenone administration was associated to a reduction in histological steatosis and attenuation of liver fibrosis development, which was associated to a significant decrease in the expression of collagen-α1, collagen type III, alpha 1 and Matrix metalloproteinase-2. CONCLUSION: The expression of MR correlates with inflammation and fibrosis development in experimental NASH. Specific MR blockade with eplerenone has hepatic anti-steatotic and anti-fibrotic effects. These data identify eplerenone as a potential novel therapy for NASH. Considering its safety and FDA-approved status, human studies are warranted.
BACKGROUND: Therapeutic options to treat Non-alcoholic steatohepatitis (NASH) are limited. Mineralocorticoid receptor (MR) activation could play a role in hepatic fibrogenesis and its modulation could be beneficial for NASH. AIM: To investigate whether eplerenone, a specific MR antagonist, ameliorates liver damage in experimental NASH. METHODS: C57bl6 mice were fed a choline-deficient and amino acid-defined (CDAA) diet for 22 weeks with or without eplerenone supplementation. Serum levels of aminotransferases and aldosterone were measured and hepatic steatosis, inflammation and fibrosis scored histologically. Hepatic triglyceride content (HTC) and hepatic mRNA levels of pro-inflammatory pro-fibrotic, oxidative stress-associated genes and of MR were also assessed. RESULTS:CDAA diet effectively induced fibrotic NASH, and increased the hepatic expression of pro-inflammatory, pro-fibrotic and oxidative stress-associated genes. Hepatic MR mRNA levels significantly correlated with the expression of pro-inflammatory and pro-fibrotic genes and were significantly increased in hepatic stellate cells obtained from CDAA-fed animals. Eplerenone administration was associated to a reduction in histological steatosis and attenuation of liver fibrosis development, which was associated to a significant decrease in the expression of collagen-α1, collagen type III, alpha 1 and Matrix metalloproteinase-2. CONCLUSION: The expression of MR correlates with inflammation and fibrosis development in experimental NASH. Specific MR blockade with eplerenone has hepatic anti-steatotic and anti-fibrotic effects. These data identify eplerenone as a potential novel therapy for NASH. Considering its safety and FDA-approved status, human studies are warranted.
Authors: Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero Journal: J Clin Endocrinol Metab Date: 2005-11-15 Impact factor: 5.958
Authors: Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe Journal: Nat Med Date: 2007-10-21 Impact factor: 53.440
Authors: Christine Guo; Vincent Ricchiuti; Bill Q Lian; Tham M Yao; Patricia Coutinho; José R Romero; Jianmin Li; Gordon H Williams; Gail K Adler Journal: Circulation Date: 2008-04-21 Impact factor: 29.690
Authors: Chloe S Chaudhury; Julia B Purdy; Chia-Ying Liu; Caryn G Morse; Takara L Stanley; David Kleiner; Colleen Hadigan Journal: Liver Int Date: 2018-03-31 Impact factor: 5.828
Authors: G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard Journal: Br J Pharmacol Date: 2016-04-26 Impact factor: 8.739
Authors: Javad Habibi; Dongqing Chen; Jack L Hulse; Adam Whaley-Connell; James R Sowers; Guanghong Jia Journal: Am J Physiol Regul Integr Comp Physiol Date: 2022-02-02 Impact factor: 3.619
Authors: Daniel Cabrera; Alexander Wree; Davide Povero; Nancy Solís; Alejandra Hernandez; Margarita Pizarro; Han Moshage; Javiera Torres; Ariel E Feldstein; Claudio Cabello-Verrugio; Enrique Brandan; Francisco Barrera; Juan Pablo Arab; Marco Arrese Journal: Sci Rep Date: 2017-06-14 Impact factor: 4.379